Absci Corp is a clinical-stage, AI-native biopharmaceutical company developing differentiated antibody therapeutics using its Integrated Drug Creation platform. The platform combines Origin-1, a generative AI model for de novo antibody design, with wet lab validation in a lab-in-the-loop approach. Its lead candidate ABS-201 targets the prolactin receptor for androgenetic alopecia and endometriosis. The company advances internal pipeline programs and offers drug creation partnerships to third parties.
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001672688-26-000068 | EDGAR | 83K words |
| 2025-03-18 | 2024-12-31 | 0001628280-25-013464 | EDGAR | 79K words |
| 2024-03-21 | 2023-12-31 | 0001628280-24-012366 | EDGAR | 77K words |
| 2023-03-30 | 2022-12-31 | 0001628280-23-009908 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001628280-22-006925 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001672688-26-000136 | EDGAR | 55K words |
| 2025-11-12 | 2025-09-30 | 0001672688-25-000084 | EDGAR | 56K words |
| 2025-08-12 | 2025-06-30 | 0001628280-25-039938 | EDGAR | 55K words |
| 2025-05-13 | 2025-03-31 | 0001628280-25-025077 | EDGAR | 53K words |
| 2024-11-12 | 2024-09-30 | 0001628280-24-046862 | EDGAR | 16K words |
| 2024-08-14 | 2024-06-30 | 0001628280-24-037193 | EDGAR | 16K words |
| 2024-05-14 | 2024-03-31 | 0001628280-24-023062 | EDGAR | 15K words |
| 2023-11-14 | 2023-09-30 | 0001628280-23-038983 | EDGAR | 23K words |
| 2023-08-14 | 2023-06-30 | 0001628280-23-029197 | EDGAR | 22K words |
| 2023-05-15 | 2023-03-31 | 0001628280-23-018165 | EDGAR | 19K words |
| 2022-11-09 | 2022-09-30 | 0001628280-22-029092 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001628280-22-022331 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-11 | 0001672688-26-000134 | EDGAR | 3K words |
| 2026-03-24 | 0001672688-26-000066 | EDGAR | 3K words |
| 2026-03-06 | 0001672688-26-000047 | EDGAR | 1K words |
| 2026-01-14 | 0001672688-26-000003 | EDGAR | 1K words |
| 2025-11-12 | 0001672688-25-000082 | EDGAR | 3K words |
| 2025-11-04 | 0001672688-25-000076 | EDGAR | 1K words |
| 2025-08-12 | 0001628280-25-039878 | EDGAR | 3K words |
| 2025-07-25 | 0001193125-25-165466 | EDGAR | 1K words |
| 2025-07-08 | 0001628280-25-034544 | EDGAR | 1K words |
| 2025-06-12 | 0001628280-25-030953 | EDGAR | 1K words |
91 total filings indexed. 64 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001672688 |
| Ticker | ABSI |
| Exchange | Nasdaq |
| SIC | 8731: Services-Commercial Physical & Biological Research |
| Website | https://www.absci.com |
| Listed | 2021-07-22 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ABSI (~200 tokens, structured JSON with cryptographic provenance)